Investor Presentaiton slide image

Investor Presentaiton

Operating Performance Analysis (RMB million) Expense Structure 2021 1H21 1H22 Gross Margin¹ 48.1% 51.3% 45.8% 11.96% YoY 39.69% YoY Selling and Distribution² 23.3% 24.8% 19.5% 1,754 1,963 1,890 1,353 Administrative 8.2% 8.6% 7.8% 1.38% YoY 434 440 Operating Results 52.25% YoY* Affected by the increased investment I in technology | development for | online operation and | increased expense for offline hospitals in | the pandemic (19) (387) Total I Pharmaceutical Med Tech Healthcare Services R&D 9.8% 9.2% 8.5% ■1H21 ■1H22 Finance 1.2% 1.7% 1.2% Operating Results Margins 1H21 1H22 Total Results Margin 10.3% 9.2% Gross Margin minus 24.8% Selling and Distribution³ 26.5% 26.2% Pharmaceutical 11.0% 13.2% 6 Note: The decrease of Gross Margin in 1H22 was mainly due to:1) the unit price increase of some core products due to the increase in labor costs and raw materials under the pandemic; 2) the lower gross margins on not self-developed Covid-19 products; 3) impact of volume based purchasing Note²: The decrease of Selling and distribution rate was mainly due to:1) continuously strengthen the control of sales expanse; 2) the decreased selling and distribution rate of volume-based purchasing products Note3: Gross Margin minus Selling and Distribution remained consistent Note: segment result increased 52.25% YoY, excluding the impact from equity transfer of Yaneng Bioscience, Med Tech 15.3% 10.9% Healthcare Services -1.1% -13.3%
View entire presentation